FDG PET in early stage cutaneous malignant melanoma
- 1 April 2014
- journal article
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 58 (2) , 149-154
Abstract
Introduction: Fluorodeoxyglucose positron emission tomography (FDG PET) is not recommended in early stage melanoma; however, a significant number of cases are referred to our institution for FDG PET. We refer to early stage disease as American Joint Committee on Cancer (AJCC) stage I and II, which includes all cases without metastases. A retrospective review was undertaken to determine the clinical utility of FDG PET in this patient group.Methods: A retrospective study of FDG scans on all patients presenting to the WA PET Centre with early stage melanoma over a 5½ year period was undertaken. The positivity rate of the initial study for detection of malignant melanoma was determined. In patients with an initially negative FDG PET, the time from initial diagnosis to a positive surveillance study was determined. Both the initial positivity rate and time to a positive study were correlated with Breslow staging.Results: Three hundred twenty‐two patients were included in the study, of which 74 had initial positive FDG PET scans (23%). Adequate follow‐up was available in 51 patients with the PET result confirmed as true positive in 37 (positive predictive value 73%). One hundred eight of 248 patients initially negative had follow‐up scans during the follow‐up period, of which 48 became positive. The 73% of recurrences were over 12 months post‐diagnosis. No correlation with Breslow thickness was demonstrated.Conclusion: Despite FDG PET not being recommended for early cutaneous malignant melanoma, 27% of melanoma cases referred for FDG PET during the study period were AJCC stage I or II. Our results suggest FDG PET in early stage melanoma demonstrates occult disease in 17% of cases.Keywords
This publication has 12 references indexed in Scilit:
- Routine FDG PET‐CT in patients with a high‐risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastasesJournal of the European Academy of Dermatology and Venereology, 2011
- Recurrence of MelanomaPET Clinics, 2011
- Nuclear Medicine in Early-Stage Melanoma: Sentinel Node Biopsy—FDG-PET/CTPET Clinics, 2011
- Melanoma of the Skin2010
- Role of PET in the Initial Staging of Cutaneous Malignant Melanoma: Systematic ReviewRadiology, 2008
- Futility of Fluorodeoxyglucose F 18 Positron Emission Tomography in Initial Evaluation of Patients With T2 to T4 MelanomaArchives of Surgery, 2006
- Inefficacy of F‐18 fluorodeoxy‐D‐glucose‐positron emission tomography scans for initial evaluation in early‐stage cutaneous melanomaCancer, 2005
- Evaluation of extensive initial staging procedure in intermediate/high‐risk melanoma patientsJournal of the European Academy of Dermatology and Venereology, 2004
- Comparison of Positron Emission Tomography Scanning and Sentinel Node Biopsy in the Detection of Micrometastases of Primary Cutaneous Malignant MelanomaJournal of Clinical Oncology, 2001
- Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanomaCancer, 1999